M ultiple randomized controlled trials (RCTs) have demonstrated the superiority of endovascular thrombectomy (EVT) in combination with intravenous alteplase over alteplase alone among patients with ischemic stroke because of large vessel occlusion (LVO).
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intravenous alteplase to control did not require pretreatment neurovascular imaging. 3, 4 Better understanding of these aspects of alteplase treatment would be helpful in determining the risks and benefits of delaying alteplase start but hastening thrombectomy start by ambulance routing of patients directly to interventional stroke centers. Additionally, the number of exclusion criteria for alteplase therapy, its cost, the time required for its mixing and infusion, and safety considerations are cited reasons 5 to justify trials randomizing LVO patients destined to undergo EVT to either receive alteplase therapy versus placebo. 6 Prior data on alteplase use in proven LVO cohorts are limited. Some studies relied on transcranial Doppler to diagnose the presence of intracranial occlusions, which is an operatordependent technique and which also might confound observational studies by introducing a sonothrombolysis treatment effect. 7 With the recent advent of large-scale EVT trials and routine EVT practice, there has been a shift in the standard stroke imaging paradigm with acute intracranial vessel imaging becoming a routine modality. In a meta-analysis, intravenous alteplase showed greater effect among patients with proven pretreatment occlusion. 8 Recent successful RCTs of EVT relied on computed tomography or magnetic resonance angiography to detect the occlusion location. Some of the trials used at least 1 extra imaging modality to assess collaterals or brain perfusion to select patients most likely to benefit from revascularization therapies. [9] [10] [11] [12] [13] [14] [15] We pooled individual patient data from patients with LVO treated with intravenous alteplase alone in the control arms of 7 recent RCTs of EVT and explored the impact of interval times adjusting for important prognostic clinical and imaging variables on functional recovery and adverse outcome.
Methods
The HERMES ( . We searched Pubmed for randomized trials published between January 1, 2010, and May 31, 2017, comparing EVT performed using predominantly stent retrievers with standard care in anterior circulation ischemic stroke patients-Pubmed search string: randomized controlled trial (publication type) and thrombectomy (title/abstract) or clot retrieval (title/abstract) or intra-arterial (title/abstract) and stroke (title/abstract) and January 1, 2010 (date/publication): May 31, 2017 (date/publication). The design and selection criteria of these trials and the HERMES collaboration have been described previously. 1 Data from these trials have been made available at the Virtual International Stroke Trials Archive, and information on access is published online at http:// www.virtualtrialsarchives.org/vista/. In brief, these trials randomized patients to receive EVT using retrievable stents (in most patients) plus medical therapy versus medical therapy alone in anterior circulation ischemic stroke patients. The current study included only medical therapy (control) arm patients who received intravenous alteplase. From this population, we excluded patients who received alteplase in a peripheral hospital before transfer to the endovascular center because among these patients, the RCTs selectively enrolled only alteplase failure patients, Alteplase was administered according to clinical routine standard care with a total dose of 0.9 mg/kg with 10% of the dose given as a bolus and the remainder infused over an hour. All participants provided informed consent according to each trial protocol, and each study was approved by the local ethics board.
This meta-analysis was prospectively designed by the HERMES executive committee but not registered. Data were contributed by the authors of all the trials meeting eligibility criteria and collated by independent statisticians. All data relevant to the analyses presented were part of each study's individual design and data collection and are part of the general HERMES database. No standardization or translation of the fields used for analysis and reporting was necessary. After collation of data, key fields were compared with original results, including published data. No major discrepancies were found, and minor discrepancies were resolved in collaboration with the study authors/investigators. The principal risk of bias derived from differences among individual study methods and inclusion criteria.
Outcomes
Global disability status at 90 days was assessed using the modified Rankin Scale (mRS). The primary outcome was the degree of disability at 90 days on the mRS, tested with the common odds ratio (OR) from a proportional odds model. Categories 5 and 6 were collapsed into one resulting in a 6-level scale. Secondary efficacy outcomes were excellent recovery (mRS, 0-1) and independent recovery (mRS, 0-2). Safety outcomes were death (mRS, 6) and symptomatic intracranial hemorrhage defined within each trial.
Statistical Analysis
We assessed outcomes using generalized linear mixed models, including a cumulative logit link function for the multinomial primary outcome of mRS and a logit link function for all other (binomial) outcomes. In all models, a term for study was included as a random effect to account for study-level variation. The relation between time and outcomes was adjusted for age, sex, baseline National Institutes of Health Stroke Scale (NIHSS) score, Alberta Stroke Program Early CT Score, and occlusion location. We also assessed for evidence of interaction between time and key baseline factors (age, sex, baseline NIHSS score, Alberta Stroke Program Early CT Score, occlusion location, diabetes mellitus, atrial fibrillation, and prior stroke). We calculated the rate of decline in benefit per 1000 patients treated by assuming linearity of the relationship and then calculating the slope of the line. All statistical analyses were performed in SAS, version 9.4 (SAS Institute, Cary, NC), and R, version 3.2 (R Foundation for Statistical Computing, Vienna, Austria). P values were 2 sided, and P <0.05 indicated statistical significance in all analyses.
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The funder of the study had no role in study design, data collection, analysis, or interpretation, writing of this article, or the decision to submit this study for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Among 893 patients in the control arms, 86 (9.6%) were excluded as being alteplase ineligible and 206 (23.1%) as receiving alteplase at a nonendovascular center, leaving 601 (67.3%) receiving alteplase at the endovascular hospital. Among these 601 patients, mean age was 66.0 years (SD, 13.9), 50% were women, and median NIHSS score was 17 (interquartile range, [13] [14] [15] [16] [17] [18] [19] [20] [21] . The median time from onset to intravenous alteplase start was 165 minutes (interquartile range, 130-203), with 82% treated within 3 hours from onset and 17% between 3 and 4.5 hours. The median door-to-alteplase treatment time Table 1 . Patients in each time treatment epoch were well matched with respect to age and sex. Earlier treated patients were less likely to have a history of hypertension and hyperlipidemia, less severe infarct signs on imaging (higher Alberta Stroke Program Early CT Score), higher acute serum glucose levels, more often had occlusions in the internal carotid artery, and presented with more severe deficits (higher NIHSS scores).
At 90 days, 18 patients were lost to follow-up. Among those with complete data, 20.2% (118 of 583) achieved excellent recovery (mRS, 0-1), and 34.1% (199 of 583) achieved independent functional recovery (mRS, 0-2). In adjusted analyses, the odds of better disability outcomes at 90 days (mRS scale distribution) in the alteplase group declined with longer time from symptom onset to treatment ( Table 2) . Each 60-minute delay in therapy was associated with a less-favorable degree of disability; common odds ratio, 0.80 (95% CI, 0.68-0.95). Each 60-minute delay was also associated with reduced odds of excellent recovery (mRS, 0-1), OR, 0.76 (95% CI, 0.58-0.99), and a trend toward reduced odds of functional independence (mRS, 0-2), OR, 0.82 (95% CI, 0.66-1.03). In adjusted analysis, the absolute risk difference for functional independence between the onset to treatment of 0.5 to 3 hours versus 3 to 4.5 hours was 4.5% (32.3% versus 27.8%; Figure 1 ). Among 42 patients with fast OTTs of 30 to 60 minutes, the adjusted rate of functional independence at 90 days was 37.5%.
The decline in the rate of good outcomes with longer onset to treatment was not modified by age (heterogeneity P=0. 21 Figure 2 ). The absolute decline in the rate of excellent outcome (mRS, 0-1 at 90 days) was 8.4 per 1000 patients treated per 15-minute delay in OTT.
The relation between door-to-needle time (DTN) and outcome was stronger than onset-to-needle time. The odds of excellent recovery (mRS, 0-1) and functional independence (mRS, 0-2) for each 60-minute delay in door-to-needle time were 0.51 (mRS, 0-1; 95% CI, 0.29-0.92) and 0.47 (mRS, 0-2; 95% CI, 0.28-0.80), respectively. The adjusted absolute risk difference for lower functional independence between DTN intervals of 0 to 30 versus 31 to 60 minutes was 19.3% (45.0% versus 25.7%). The absolute decline in the rate of excellent outcome (mRS, 0-1 at 90 days) was 20.3 per 1000 patients treated per 15-minute delay in DTN. There was no evidence of an OTT effect on mortality or symptomatic intracranial hemorrhage (Table 2) .
Discussion
In this pooled analysis of individual participant-level data of patients with acute ischemic stroke with documented LVO receiving alteplase alone, 20% of patients achieved excellent functional outcome at 90 days. Slower initiation of alteplase therapy was associated with worse outcomes over the entire disability range and lower rates of excellent recovery and functional independence. In contrast, death and symptomatic intracranial hemorrhage did not show OTT dependency. The rate of decline of benefit with time from symptom onset was modest, although clinically relevant at the systems level; among patients with LVO, every 15-minute delay in alteplase start is associated with 8 fewer among 1000 patients achieving excellent (mRS, 0-1) outcome at 90 days. In contrast, the rate of decline of benefit with time from hospital arrival (DTN) was more dramatic among patients with LVO, every 15-minute delay in alteplase start is associated with 20 fewer among 1000 patients achieving excellent (mRS, 0-1) outcome at 90 days.
These findings are consonant with prior studies demonstrating that alteplase treatment is of benefit for a broad range of patients with acute ischemic stroke treated within 3 hours 14 and within 3 to 4.5 hours from the last-seen-well time. 16 Treatment outcomes in general clinical practice accord with those in the pivotal RCTs, in diverse geographic regions and healthcare systems. [17] [18] [19] Among this broad patient group, both pooled clinical trials and large clinical practice registries also demonstrated a large time dependency of benefit from treatment with intravenous alteplase, with treatment sooner after onset associated with improved outcomes. 2, 20, 21 Disability outcomes at 3 months after treatment with intravenous alteplase alone were less favorable among patients with LVO in the current investigation than among broader cohorts investigated previously. The overall rate of functional independence at 90 days among patients with LVO of 34% in the current study is much less than the 44% seen among a broader cohort in the pooled pivotal intravenous alteplase trials. 22 This less-favorable outcome rate is consistent with the greater presenting deficit severity and the reduced early reperfusion response of LVO compared with non-LVO patients.
The pace of loss of benefit from stroke onset to alteplase therapy specifically in patients with LVO, observed in the current study, appears slightly faster than that for the broader group of all alteplase-eligible patients. Direct comparison with prior studies is not possible because the time-benefit curve analysis of pooled patients from all alteplase trials reported changes with onset to treatment in the OR for better outcomes with alteplase versus control but not the speed of decline in good outcomes within the alteplase-treated group. 2 The timebenefit curve analysis of patients treated in practice in the US national Get With The Guidelines-Stroke registry reported changes with onset to treatment in rates of good outcome at discharge, rather than at 90 days, but the results are similar. 20 In the current study, a 15-minute delay in start of alteplase was associated with 8 fewer of 1000 patients with LVO achieving excellent (mRS, 0-1) outcome at 90 days; in the US national registry study, a 15-minute delay in start of alteplase was associated with 7 fewer of 1000 mixed LVO and non-LVO patients achieving excellent (mRS, 0-1) outcome at hospital discharge.
A critical observation from the current study is the documentation of the large absolute magnitude of benefit with fast DTNs, with an estimated number needed to treat of 5 to achieve 1 additional independent outcome with treatment <30 minutes from hospital arrival compared with >30 minutes. This result implies an imperative to set standards for in-hospital processes much more aggressively than currently. Although ultimately the onset-to-reperfusion times will physiologically govern the chance of good outcome, the patients in the HERMES analysis were largely selected by imaging characteristics such that
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March 2019 patients with large infarcts (on noncontrast computed tomography, magnetic resonance, or predicted by computed tomography perfusion) or poor pial collateral filling were excluded. This meant that the onset-to-imaging time was less important than the imaging-to-treatment times in predicting outcomes. In addition, there is substantive inaccuracy of documented lastknown-well times, dependent on the recall of patients with acute brain insults or on symptom recognition by proxy observer, introducing noise into onset-to-treatment intervals absent from door-to-needle intervals. These physiological, measurement, and trial design factors likely contribute to the large magnitude of effect size difference between DTNs and OTTs.
The decline in benefit because of delays from onset to treatment with alteplase therapy alone in patients with LVO in the current study is 2.5-fold less (8 versus 20 fewer per 1000 independent outcomes per 15-minute delay) than that for EVT in patients with LVO in a prior US national Get With The Guidelines-Stroke study. 23 This is consistent with the larger overall treatment benefit magnitude associated with endovascular therapy. However, patient selection by imaging may also play a role in the shallow OTT decay curves for intravenous alteplase treatment patients, by excluding patients with fast progression of ischemia. Although the Get-WithThe-Guidelines data are voluntarily collected and reported compared with the more rigorous prospective clinical trial data presented here, these contrasting time-benefit relationships are important inputs into models seeking to optimize ambulance routing strategies for patients with suspected LVO because direct routing to comprehensive stroke centers will cause longer onset to treatment for alteplase but shorter onset to puncture for thrombectomy. 24 Biologically, our results may be partly explained because the probability of early reperfusion with intravenous alteplase only is less than half that with EVT. In the ESCAPE trial, 10 recanalization was measured in the control arm at 2 to 8 hours after randomization using computed tomographic angiography. Despite differences in subpopulations, the rate of early recanalization was 7% in those who were not eligible for and did not receive alteplase, 37% in those who received alteplase alone, and 75% in those who received EVT (determined by formal selective cerebral angiography). 10 Key baseline patient factors, including stroke severity and the extent of early ischemic changes, did not alter the time relationship with treatment. Although the European regulation labeling for alteplase in the 3-to 4.5-hour time window, using ECASS-3 data, 16 initially suggested that patients >80 years of age with diabetes mellitus or severe stroke should not be offered treatment with alteplase, our analyses provide collateral prospective observational evidence that fast treatment is the more important issue.
This study has limitations. Entry criteria differed in some ways across the 7 contributing trials, most notably with 3 of the trials requiring or encouraging the use of more advanced imaging of penumbra or collaterals. However, among patients with LVO, almost all patients have adequate penumbra or collaterals within the first 4.5 hours from onset. Only 1 trial collected data on early reperfusion subsequent to alteplase use, precluding detailed analysis. We made a simplifying assumption that all patients treated at the endovascular hospital had computed tomography angiograph before or immediately after commencing alteplase therapy; however, it remains possible that this was not the case in a small number of patients. The nature of some of the trial protocols 
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resulted in an enriched cohort who did not reperfuse with intravenous alteplase (nonresponders), which may have resulted in an underestimate of the rate of excellent neurological outcome. Finally, even after pooling across trials, sample size was moderate, limiting precision of time-benefit relation estimates.
In conclusion, disability outcomes at 3 months with alteplase alone are less favorable with slower OTTs. Faster treatment, in particular DTNs <30 minutes, are strongly associated with better outcomes.
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